We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Swift Biosciences, SeraCare Partner
News

Swift Biosciences, SeraCare Partner

Swift Biosciences, SeraCare Partner
News

Swift Biosciences, SeraCare Partner

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Swift Biosciences, SeraCare Partner "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Circulating tumor DNA (ctDNA) detection, also called a ‘liquid biopsy’, is a needed application of next-generation sequencing (NGS) to detect cancer mutation signatures directly from blood plasma samples for patients with tumors that cannot be biopsied.

Seraseq™ ctDNA products are based upon patent-pending technology used to make circulating fetal DNA reference materials. Mixtures of DNA containing key somatic mutations at specific allelic frequencies are provided as stabilized material in a proprietary synthetic plasma matrix.

The first ctDNA reference material available for early access is a 9-mutation mixture at varying allele frequencies targeted from 5% down to 0.1%. The Seraseq circulating nucleic acid technology is robust and highly amenable to customization, supporting any number of mutations and allele frequencies as quantitated by digital PCR (dPCR). The combination of design and stabilization technology results in a highly precise and reproducible ‘ground truth’ material suitable for NGS and dPCR assay development and performance monitoring.

“Swift Biosciences has been instrumental in providing leading NGS-based assay results using their unique library construction enzymology and target enrichment chemistry”, said Russell Garlick PhD, CSO of SeraCare Life Sciences. “With Swift’s Accel-Amplicon™ Oncology panel, we have observed reliable and consistent results with our Seraseq ctDNA biosynthetics to allele frequencies below 1%.”

Swift Accel-Amplicon panels offer a streamlined workflow and all materials necessary for complete library construction, with the low input requirements necessary for materials such as ctDNA and FFPE samples. As use of liquid biopsy for translational research grows, customized panels with low sample inputs and high sensitivity become essential requirements for NGS-based assays.

“Reference standard material for circulating tumor DNA is vital for the implementation of liquid biopsy analysis,” said Dr. Timothy Harkins, CEO of Swift Biosciences. “Understanding and characterizing any NGS assay for liquid biopsy samples will require well-defined reference reagents. Standards like Seraseq ctDNA reference material allow the community to first understand ctDNA properties, optimize assays and then ultimately use ctDNA in innovative assays to detect and monitor cancer burdens within samples. In turn, this type of work will lay the foundation for transforming future cancer treatments.”

Advertisement